Skip to main content
Clinical Trials/NCT02117726
NCT02117726
Unknown
Phase 4

Impact of Various Sedation Regimens on the Incidence of Post-sedation Delirium in Patients Receiving Mechanical Ventilation

Shandong Provincial Hospital7 sites in 1 country320 target enrollmentMay 2014

Overview

Phase
Phase 4
Intervention
Dexmedetomidine,midazolam
Conditions
Delirium
Sponsor
Shandong Provincial Hospital
Enrollment
320
Locations
7
Primary Endpoint
Incidence rates and duration of delirium
Last Updated
11 years ago

Overview

Brief Summary

Sedation drugs that are commonly used in ICU in treatment of ARDS, includes propofol, midazolam and dexmedetomidine . Among these, both dexmedetomidine and propofol have been reported to be used together with midazolam in ICU and the combination of propofol and midazolam is most commonly used, but things follow include a high incidence rate of delirium, But the combination of midazolam and dexmedetomidine may have complementary advantages and could have be a better choice for sedation. In this study, we attempted to observe the effects of two different drug regimens on delirium incidence rates in severe ARDS patients' : midazolam and propofol vs propofol and dexmedetomidine .

Registry
clinicaltrials.gov
Start Date
May 2014
End Date
December 2015
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Wangchunting

Director

Shandong Provincial Hospital

Eligibility Criteria

Inclusion Criteria

  • Subjects willing to give written informed consent.
  • Mild, moderate or severe ARDS patients demanding invasive mechanical ventilation.
  • Subjects whose expected time of mechanical ventilation is longer than 24 hours.
  • Subjects aged between 18 and 70.

Exclusion Criteria

  • Subjects with extremely unstable circulation, whose SBP lower than 90mmHg after volume expansion or pressor agent treatment.
  • Subjects with extremely unstable circulation, whose SBP lower than 90mmHg after volume expansion or pressor agent treatment.
  • Subjects with heart rates less than 50 beats per minute.
  • Subjects with second or third degree atrioventricular block.
  • Subjects with serious cerebral injury, severe neurologic disorder (e.g acute stroke, uncontrolled epilepsy and severe dementia) or coma.
  • Subjects with acute or severe liver disease (Child-Pugh class C), see attachment
  • ARDS patients caused by pulmonary fibrosis or COPD.
  • Subjects on all types hemodialysis.
  • Subjects with neuromuscular system disease, alcohol withdrawal syndrome or mental disease before entrance of ICU.
  • Subjects suspected of narcotic analgesics abusing.

Arms & Interventions

Dexmedetomidine,midazolam

Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02\~0.1mg/kg/h, for 24 hours.Dexmedetomidine will be added at 0.2\~1.4μg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of dexmedetomidine, continuous intravenous infusion of midazolam could be used at 0.02\~0.1mg/kg/h, until the target level is reached.

Intervention: Dexmedetomidine,midazolam

Propofol,midazolam

Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02\~0.1mg/kg/h, for 24 hours.Propofol will be added at 0.3\~4mg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of propofol, continuous intravenous infusion of midazolam could be used at 0.02\~0.1mg/kg/h, until the target level is reached.

Intervention: Propofol,midazolam

Outcomes

Primary Outcomes

Incidence rates and duration of delirium

Time Frame: up to 15 days

Incidence rates and duration of delirium within 14 days after initiation of sedation with dexmedetomidine or propofol

Sedation interruption

Time Frame: up to 5 days

Eye opening according to the voice orders, eye tracking, clenching fist and nodding are involved in assessment, patients could do 3 of those or more is deemed as conscious and taken in delirium assessment.

Secondary Outcomes

  • Hospitalized days in ICU(up to 15 days)
  • Variation degree of HR, RR, BP and SpO2(up to 15 days)
  • Sedation therapy effect(up to 7 days)
  • Death rates(28 days)
  • Incidence rate of patients self-extubation(up to 7 days)
  • Injection speed, total dose and injection of sedatives in different groups.(7 days)
  • Additional dose of fentanyl and midazolam(up to 7 days)
  • Dosage of diuretic, antiemetic, hypoglycemic, beta-receptor antagonist and vasoactive agents.(up to 15 days)

Study Sites (7)

Loading locations...

Similar Trials